Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Goldman Sachs raised the firm’s price target on Schrodinger (SDGR) to $28 from $27 and keeps a Neutral rating on the shares. The company’s Q3 results and announced deal with Novartis (NVS) involving ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to ...

Schrödinger, Inc. today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis's portfolio for further development. The ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Schrödinger Inc.’s stock soared 14% Tuesday to put in on track for its biggest one-day gain in a year, after the company said ...

In a significant stride within the pharmaceutical industry, Midtown's own Schrödinger has clinched a deal with healthcare ...

Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the third quarter of 2024 and provided a business update. In a separate press release issued earlier ...